for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nichi-iko Pharmaceutical Co., Ltd.

4541.T

Latest Trade

1,375.00JPY

Change

-31.00(-2.20%)

Volume

242,700

Today's Range

1,374.00

 - 

1,402.00

52 Week Range

1,072.00

 - 

1,907.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,406.00
Open
1,401.00
Volume
242,700
3M AVG Volume
4.84
Today's High
1,402.00
Today's Low
1,374.00
52 Week High
1,907.00
52 Week Low
1,072.00
Shares Out (MIL)
63.85
Market Cap (MIL)
92,661.29
Forward P/E
14.19
Dividend (Yield %)
2.11

Next Event

Q3 2020 Nichi-Iko Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Sagent Pharmaceuticals Announces FDA Acceptance Of Omega Manufacturing Site

Nichi-Iko Pharmaceutical announces exercise of options

Nichi-Iko Pharmaceutical announces exercise of options

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nichi-iko Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co.,Ltd. is a Japan-based company principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed.

Industry

Biotechnology & Drugs

Contact Info

1-6-21, Sogawa

+81.76.4322121

https://www.nichiiko.co.jp/

Executive Leadership

Yuichi Tamura

President, Representative Director

Kenji Akane

Executive Vice President, Director

Noboru Inazaka

Senior Managing Executive Officer, Chief Director of Administration, Director

Takahiro Yoshikawa

Managing Executive Officer, Chief Director of Procurement, Director

Toru Ishizu

Managing Executive Officer, Chief Director of Development & Planning

Key Stats

3.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (JPY)

2017

84.090

2018

143.190

2019

115.460

2020(E)

100.186
Price To Earnings (TTM)
17.06
Price To Sales (TTM)
0.53
Price To Book (MRQ)
0.79
Price To Cash Flow (TTM)
5.99
Total Debt To Equity (MRQ)
107.24
LT Debt To Equity (MRQ)
75.06
Return on Investment (TTM)
2.56
Return on Equity (TTM)
1.73

Latest News

Latest News

BRIEF-Nichi-Iko Pharmaceutical to start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko"

* Says it will start sales of Infliximab BS for I.V. Infusion 100mg "Nichi-Iko" on Nov. 29

BRIEF- Nichi-Iko Pharmaceutical says merger with wholly owned unit

Nichi-Iko Pharmaceutical Co Ltd * Says it merged with a wholly owned unit, on Oct. 1 Source text in Japanese:https://goo.gl/Zi3Hxh Further company coverage: (Beijing Headline News)

BRIEF-Nichi-Iko Pharmaceutical and unit says marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" and "AYUMI"

* Says it received marketing approval for Infliximab BS for I.V. Infusion 100 mg "Nichi-Iko" from the Ministry of Labour, Health, and Welfare on Sept. 27

BRIEF-Nichi-Iko Pharmaceutical to merge with wholly owned subsidiary

* Says it plans to merge with a wholly owned subsidiary, which is engaged in manufacture of pharmaceuticals

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up